Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-09-23
2008-11-25
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266200, C514S266220, C514S266240, C544S283000, C544S293000
Reexamination Certificate
active
07456189
ABSTRACT:
Compounds of the formulahaving an inhibitory action on the signal transduction mediated by tyrosine kinases, and being useful for the treatment of oncoses and of benign prostate hyperplasia (BPH), of diseases of the lung and of the airways. Exemplary compounds are:(R)-4-(1-Phenylethylamino)-6-[1-(tert-butyloxycarbonyl)piperidin-4-yloxy]-7-methoxy-quinazoline and(R)-4-(1-Phenylethylamino)-6-(piperidin-4-yloxy)-7-methoxyquinazoline dihydrochloride.
REFERENCES:
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5770599 (1998-06-01), Gibson
patent: 5866572 (1999-02-01), Barker et al.
patent: 6362336 (2002-03-01), Lohmann et al.
patent: 6399602 (2002-06-01), Barker et al.
patent: 6414148 (2002-07-01), Thomas et al.
patent: 6617329 (2003-09-01), Himmelsbach et al.
patent: 6627634 (2003-09-01), Himmelsbach et al.
patent: 6645969 (2003-11-01), Myers et al.
patent: 6656946 (2003-12-01), Himmelsbach et al.
patent: 6924285 (2005-08-01), Himmelsbach et al.
patent: 7196091 (2007-03-01), Himmelsbach et al.
patent: 2002/0049197 (2002-04-01), Himmelsbach et al.
patent: 2002/0082271 (2002-06-01), Himmelsbach et al.
patent: 2002/0177601 (2002-11-01), Himmelsbach et al.
patent: 2003/0149062 (2003-08-01), Jung et al.
patent: 2004/0048880 (2004-03-01), Himmelsbach et al.
patent: 2005/0070560 (2005-03-01), Himmelsbach et al.
patent: 2005/0159436 (2005-07-01), Himmelsbach et al.
patent: 2005/0182043 (2005-08-01), Himmelsbach et al.
patent: 2006/0264450 (2006-11-01), Himmelsbach et al.
patent: 2006/0270672 (2006-11-01), Himmelsbach et al.
patent: 0566226 (1993-10-01), None
patent: 0787722 (1997-08-01), None
patent: 9633980 (1996-10-01), None
patent: 9722596 (1997-06-01), None
patent: 9730035 (1997-08-01), None
patent: 9732856 (1997-09-01), None
patent: 9738983 (1997-10-01), None
patent: 9813354 (1998-04-01), None
patent: 9843960 (1998-10-01), None
patent: 9901467 (1999-01-01), None
patent: 9906396 (1999-02-01), None
patent: 9909016 (1999-02-01), None
patent: 0018740 (2000-04-01), None
patent: 0051991 (2000-09-01), None
patent: WO 00/55141 (2000-09-01), None
patent: 0078735 (2000-12-01), None
patent: 0177085 (2001-10-01), None
patent: 0177104 (2001-10-01), None
patent: WO 02/18351 (2002-03-01), None
patent: WO 02/18372 (2002-03-01), None
patent: 0250043 (2002-06-01), None
patent: WO 03/082290 (2003-10-01), None
Goldkorn, T. et al. “EGF-Receptor Phosphorylation . . . ” Am. J. Respri. Cell. Mol. Biol., 1998, vol. 19, pp. 786-798.
Tang, P.A. et. al. “A review of erlotinib and its clinical use” Expert Opinion Pharmacotherapy, 2006, vol. 7, No. 2, pp. 177-193.
International Search Report Reference #PCT/EP2004/010723.
Himmelsbach Frank
Jung Birgit
Boehringer Ingelheim International GmbH
Devlin Mary-Ellen M.
Morris Michael P.
Stempel Alan R.
Truong Tamthom N
LandOfFree
Bicyclic heterocycles, medicaments containing these... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic heterocycles, medicaments containing these..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic heterocycles, medicaments containing these... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4037524